afternoon, you recent business Thank us third provide of overview Sheri. time once an results. today and as and discuss join financial the taking Good quarter highlights our to you, for we again everybody, XXXX thank
we'll for the recent review our the for is by me today I'll come a financials, and then Mr. for both call quarter then clinical back over third our begin Andrew Andrew of Financial call Joining reviewing and to call corporate Officer. Q&A. in Sims, the Chief progress the and turn our
the ReSPECT-LM therapeutic we (XXXRe) in I'll of leptomeningeal lead are begin our which program investigating metastases afternoon our Rhenium this in radio overview with Obisbemeda trial. an
dose for XX is of of research Obisbemeda in trial, call, ongoing is closing [indiscernible] dose of this development brevity. on name substantial LM program single as millicuries. I'll in perhaps for forward approximately RNL, going a Rhenium now, administration very RNL maximum sake I As (XXXRe) Phase we refer respect a our which escalation our Part administer the for its which to
Data and X a that plan the recommended millicuries, compassionate Part subset to [indiscernible] treated. Board we development expand fully have patients well LM to Safety Board, X first phase a doses to is trial responded who proceeding lesser agreement has in the with XX a QX, modified for been dose under initial ReSPECT more multiple and reached and received a trial. to dose XX use. are I'll to dose Relatedly, site including date, X of integrated Cohort of of in administration proceed patient I Monitoring design our dose Phase the currently start-up multiple review protocol, that trial under we and moment. FDA escalation the a multiple in trial. To
the Single through Conference SNOW terms X X. Administration August ReSPECT-LM clinical at In through of in data presented update ASCO Trial, the interim an from we Cohorts
full non-small XX favorable quite approximately post-treatment. website. presentation through available which X, key highlights months reported months very consensus XXX Doses a is compared survival and meeting and are no up to Cohorts presentation. to on with average means a found therapeutic about Here from demonstrated ratio. that historically was dose-limiting X target that be X lung safe XX tumor Through XX% of And treatment of cell well day through were cancer. off-target Pharmacokinetic reduced XX data the RNL our from toxicities. overall with on X specifically to were to Cohorts is XX index, cells breast in high circulating millicuries at the for median X tolerated The
PD with XX a Houston, trial important dose Later to single Cohort on PK, which this we survival through administration response through in SNOW; data. escalation at going month, provide Meeting, will I including the November and Society for is update X the Neuro-Oncology comprehensive Annual Phase new be data, XX
We ], leading Kumathekar and with [ Jonathan subject symposium also experts, Dr. Priya Yang matter a the will Dr. detail discuss Dr. greater to in Andrew data host Brenner.
LM. a As admiration administrations I dose the open-label for with mentioned safety, assess patients identify before, safety and multiple of we and dose of RNL value long-tail in of frequencies. and patients initiate multiple intervals escalation Phase at specifically, enrollment outcomes doses administration from of administration FDA maximum with our RNL X-part feasible the in and reinforced dose tolerated already obtain RNL multiple patients various survival trial regime Phase aimed dosing objectives I safety in multiple agreement patients doses ReSPECT-LM tolerability reached have at More treating intervals the observed with LM. to dose to Favorable with potential an receiving the single of dosing study [indiscernible] I evaluating maximum doses to LM. the efficacy trial to both the Primary multiple is administering and of and trial
The include response survival. secondary objectives evaluating and
provide up RNL and the U.S. every dose trial minimum treat in of administering for cohort. QX approval [indiscernible] integrated with The XX doses days doses days of details expected development -- I Phase intervals, at XX.X finally, to shorter part SNOW plan patients escalation progressively at plan first ReSPECT-LM being utilize administration trial. in single millicuries at Conference days in The to enrollment a XXXX the at potentially Annual at and We then on X and then X the starting patients begin further X sites to study aim XXXX XX every will path cancer leptomeningeal trial our current to at XX XX is to Houston. the and enrolling to up active
Now the diagnostic and cerebrospinal a the we treatment by RNL of The of monitoring lab or oncologists CNS LM patients neuro-oncologists, fluid used diagnosis, petitioners LDTs, well assay or cerebrospinal for risk be patients platform other inside for selection LM as or or for CNSide investigation importance are fluid medical Increasingly, at the for malignancies. broader our in and neuro-immunologist, of see may with at platform group discussion other recognizing value commercial as the X LM other our both malignancies. product assay tests CNS as diagnostic risk in of consists of for assays around a stand-alone the developed and
terms related January. CNSide In the market in to launch planned of access activities
As testing, you Houston, earlier obtained following we X and intend registration which was Step QX may CMS. transfer X; inspection initiating Texas, in tech of in to and compliance CLIA by year. completed of owned certificate recall, CLIA we based XXXX obtain lab Step certificate this in QX, was fully sub a a
test and Diagnostics payers it apply health understand of both . claims. the to ensure pre-authorization helps also being This will for quarter, or Exchange expanded care with is automate we drilled, which allows a and that payers the which Z-code to reimbursement adjudication providers
Blue is Z-Code Cross such Shield forth. the as UnitedHealthcare, Blue Medicare, payers well-known Specifically Humana, and so required by
number previously place accuracy standards identifies and for above, Medical a payers, the receipt code Code, quarter, to assay. Laboratory the American and Next with federal with the complex the is CLIA the mentioned or Medicare ensuring following had are This specifically to for for required certificate compliance, for of testing, test. Analysis safety we of labs meet further code we and agreements by PLA commercial negotiating PLA quality, parallel in which intend these of code CNSide CPT Proprietary a Association. they apply certifies In activities
payers we trials. be the number agreements put the enumeration platform the Specifically, owner previous place. Also, we're be commercially clinical make regions CNSide, we and of the test new containing again and ReSPECT-LM in them are that the plan available will informing focused acquired from from LVT and LM in to to the Currently, tumor cover that used to patients. cell highest CNSide continues assets
to track of of U.S. the commercially on reintroduce market release as part in XXXX. a limited are We in test the January
test as forecasted and time, same assays a limited our are way biomarker basis investment specific toward expanded the and test assays specifically and the growth costs In economics. talk XXXX diagnostic about in ramp expanding menu market will secret rolling XXXX. include test related cellular the to we meaningful current will guide by offset in more post At a in XXXX, we we'll grant. access, more on Aggregate are that CNSide molecular remain
ReSPECT-GBM completing with to and to patients completed, glioblastoma than dose that October evaluating clinical limited II data evaluates with Phase be study XX ReSPECT-GBM tumors RNL with patients year. trial we I Enrollment and the the been this ReSPECT-GBM Phase of final gears has mls, Meeting report. trial equal in a the than of which shifting in recurrent XXXX into Now the Phase Enrollment recurrent to update will I at [indiscernible] greater glioblastoma. or patients for Congress continues trial The Annual our lesser single for in last for Neurological portion was mls. XX
across enrolled of that a patients at reminder, highlights a been As total time. XX key X sites include had
severe and to XXX dose was that with critical radiation moderate of survival. drug. Phase XX% or improved highly related is correlative events X correlated XXX survival. preclinically gray, [indiscernible] the Furthermore, In well events adverse Only Phase Phase deemed increased the the average of mild systemic remains patients in most II, with unrelated the I adverse gray above drug approximately half to II tumors the and to also X in served to study Moreover, absorb drug achieved radiation delivery overall study parameters low. were were exposure over
treated have benefit effective continues dose, receiving above to we -- to to and Phase control new areas. we tumor showed ReSPECT-GBM the doses analysis patients control from a within trial pivotal substantial tumor of tumor showed a volume enrollment are XXX trial. between analysis sites support, volume statistically bud added cerebral and pleased X both potentially volumetric announce the Finally, II relationship The clinical using trial NIH absorb large support gray, response significant and specifically
Northwell provides York North Ohio the part Shore us area. and added We've and metropolitan University, in Hospital, Midwest the Lenox which New in Hill of coverage Upper the State Network
sites patients second midyear with we data these completion II a new With readout the XX patients in additional of screening XXXX. total in expect for XXXX activated half and X Phase enrollment by
that Additionally, married develop brain Device software procedure software-driven implement cancers. recently CED their treatment and patients, we for planning execution we like to announce of to RNL delivery company anticipated improve GBM to precise outcomes. entered Ecosystem enhance more collaboration for planning, delivery technology agreement research will into patient optimized Brainlab's drug and to Brainlab, a further software convection-enhanced would case medical and or with a
have Approximately Award for received announced we of with a U.S. and program. just [indiscernible]. children a brain Phase high-grade a a support Department trial we bit to grant glioma Defense substantially Now our of $X I previously as $XXX,XXX pediatric drug about million to the cancer production payment half pediatric award. approval that moving part IND and Chicago on Hospital was first as in in obtaining initial serving of clinical the trial -- received of We XXXX manufacturing. in anticipate September the of Children's And [indiscernible] site. the Recall,
we of this materials To to the with capable registrational potential have terms intermediates for We reliable with are from expanding completed commercial process XX,XXX dose, RNL, doses future approximately in manufacturing multiple to the and capacity capabilities around to qualification level demand batch single a and batch support production this and at doses time ensure second of pilot partnership, of year up projections. dosing of time scale GMP announced SpectronRx. per GMP anticipated our process opportunity approval. Through we scale single per manufacturing recently a partnership, transition of redundancy building FDA trials our supply
Can Andrew, discussion a turn you about to for Andrew? i financials. over the So it
